ClinicalTrials.gg
TerminatedNCT02963103Updated Nov 23, 2016

A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen

A Phase 4 interventional study of Tacrolimus in Kidney Transplantation, sponsored by Astellas Pharma Korea, Inc.. Terminated at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-11-23.

Sponsored by Astellas Pharma Korea, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

Why this study was terminated
Sponsor decision to terminate the study because subject enrollment was difficult.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

The objective of this study is to observe and evaluate the change in renal function following conversion from cyclosporine-based immunosuppressive regimen to tacrolimus-based one.

02

Conditions studied

  • Kidney Transplantation

Keywords

  • Tacrolimus
  • Kidney transplantation
03

In context

Lead sponsor

Astellas Pharma Korea, Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients received a kidney transplant at least 12 months before enrollment.
  • Patients whose dosage of previous has not been changed and remained for at least 4 weeks before enrollment, and blood trough level of cyclosporine is 100 to 200 ng/mL.
  • Patients who have the side effects (hypertension, hyperlipidemia, gingival hyperplasia and hypertrichosis/hirsutism) during use of cyclosporine.
  • Serum creatinine \< 2.3 mg/dl at enrollment
  • Female patients of must have a negative serum pregnancy test prior to enrollment, and agreed to use effective during the trial.
  • Patients considered clinically stable

Exclusion criteria

Exclusion Criteria:

  • Patients who have previously received an organ transplant other than a kidney.
  • Patients who have had acute transplant rejection within 12 weeks, or acute transplant rejection requiring antilymphocyte therapy within 24 weeks prior to enrollment.
  • Patients newly diagnosed malignant tumors after organ transplant, but the patients treated completely with basal or squamous cell carcinoma of the skin are excepted.
  • Patients who have an underlying disease such as focal segmental glomerulosclerosis (FSGS) or type II membranoproliferative glomerulonephritis (Type II MPGN).
  • Proteinuria > 2 g/24 hrs.
  • Patients who have "Creeping creatinine" (a 20% increase in their creatinine for six months before their enrollment).
  • Patients whose (ALT) and/or Aspartate Aminotransferase (AST) is twice higher than the normal range in the center.
  • Patients who have liver cirrhosis.
  • Patients who are pregnant or breastfeeding.
  • Patients who had been -positive.
  • Patients who have a known allergy to Prograf® or its ingredients, or adjuvants.
  • Patients who have an unstable medical condition that may affect the evaluation of the study's objectives.
  • Patients who are receiving prohibited concomitant medications or who received those medications within 28 days of their enrollment.
  • Patients who are currently participating in another clinical trial or who received the drug in another trial within 28 days of their enrollment.
  • Patients who are at the risk of drug abuse or mental disorders or communicate difficulties.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Tacrolimus group

    oral

    Drug: Tacrolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in GFR

    GFR: glomerular filtration rate

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change from baseline in total cholesterol

    Time frame: Baseline and Week 24

  2. Change from baseline in Triglycerides

    Time frame: Baseline and Week 24

  3. Change from baseline in LDL

    LDL: low density lipoprotein cholesterol

    Time frame: Baseline and Week 24

  4. Change from baseline in HDL

    HDL: high density lipoprotein cholesterol

    Time frame: Baseline and Week 24

  5. Change from baseline in the number of antihyperlipidemic drugs

    Time frame: Baseline and Week 24

  6. Change from baseline in blood pressure

    Time frame: Baseline and Week 24

  7. Change from baseline in the number of antihypertensive drugs

    Time frame: Baseline and Week 24

  8. Change from baseline in number of participants who have had hirsutism

    Investigator's judgment

    Time frame: Baseline and Week 24

  9. Change from baseline in number of participants who have had gingival hypertrophy

    Investigator's judgment

    Time frame: Baseline and Week 24

  10. Overall incidence rate of adverse events

    Time frame: up to Week 24

  11. Proportion of participants with patient survival

    Time frame: up to Week 24

  12. Proportion of participants with organ survival

    Time frame: up to Week 24

  13. Acute rejection rate confirmed by biopsy

    Time frame: up to Week 24

  14. Ratio of mean dose of cyclosporine to tacrolimus

    Time frame: up to Week 24

07

Study locations

1 site
  • KR00001
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2016
First posted
Nov 15, 2016
Start
May 2010
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Last update
Nov 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02963103
Responsible party
Sponsor
First posted
Nov 15, 2016
Start date
May 2010
Primary completion
Oct 2012
Completion
Oct 2012
Last update
Nov 23, 2016

Study contacts

Medical Director
study director · Astellas Pharma Korea, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion